| Contact |
General |
Specializations in Countries |
Contribution to the Global Plan |
Declaration |
View this partner's profile
Organization Contact Information |
| Name: |
Hongqi Pharmaceutical |
| Street 1: |
No. 6 Xinluo St |
| Street 2: |
Hunnan New District |
| City: |
Shenyang |
| Province: |
Liaoning |
| Post Code: |
|
| Country: |
China |
| Phone: |
+86 (24) 23786268-8009 |
| Organization Email: |
chenmingming@hongqipharma.com |
| Web Site: |
http://en.hongqipharma.com/ |
| Other Online Presence: |
|
Focal Point Contact Information |
| Salutation: |
Ms |
| First Name: |
Mingming |
| Last Name: |
Chen |
| Title: |
International Business Manager |
| Email: |
chenmingming@hongqipharma.com |
| Phone: |
+86 18540059356 |
|
Alternate Focal Point Contact Information |
| Salutation: |
NA |
| First Name: |
NA |
| Last Name: |
NA |
| Title: |
|
| Email: |
NA |
| Phone: |
|
|
General Information |
| Board Constituency: |
Private sector |
| Is your organization legally registered in your country: |
Yes |
| If yes, please enter your registration number: |
|
| Organization Type - Primary: |
Private Sector |
| Organization Type - Secondary: |
Company |
| Organization Description: |
| Shenyang Hongqi Pharmaceutical Co.,Ltd established in 1964, located at Shenyang ,Liaoning province. One of the Chinese Anti Tuberculosis Association member. Hongqi pharma is currently subordinate to shanghai Fosun Pharmaceutical (Group) Co., Ltd.(Stock Number:600196-SH, 02196-HK).Hongqi Pharma is one of the best anti-tuberculosis Pharmaceutical in China. We follow the principle of “no more human being should suffer Tuberculosis in the future”. Hongqi Pharma research and develop anti-tuberculosis drug since 1986, after all the research and development for thirty years, we become one of the largest production base for anti-tuberculosis drugs in China. Hongqi Pharma is specified drug manufacture by “Ministry of Health”. Hongqi Pharma will become one of the top entrepreneur in global anti-tuberculosis business.Hongqi Pharma owns 1st line anti-tuberculosis production line include: Rifampicin Capsule, Rifampicin Capsule II, Isoniazid Tablet, Ethambutol Hydrochloride Capsule/Tablet, Pyrazinamide Capsule/Tablet, Protionamide Enteric-coated Tablet, FDC productions. Especially FDC production qualify for the demand of standardized treatment, which provides convenience for the China CDC to help the patients with free medication. |
| |
| Do you know about the UNHLM declaration: |
|
Specializations / Areas of Work |
Funding, including innovative and optimized approach to funding TB Care
Provision of drugs, diagnostics and commodities
|
Other Organization Information |
| Total number of staff in your organization: |
100 + |
| Number of full-time staff who are directly involved with TB: |
100 + |
| Number of part-time staff who are directly involved with TB: |
51 - 99 |
| Number of volunteers who are directly involved with TB: |
0 |
| |
| How did you hear about the Stop TB Partnership: |
Internet search |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: |
|
| Why do you wish join the Stop TB Partnership: |
Information on developments within the TB world |
| |
| Are you a member of a Stop TB national partnership: |
No |
| Are you in contact with your national TB programme: |
Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: |
| We supply 85% goverment procurement in China. The funder of “Double Thousand”Foundation. |
| |
Geographical Reach |
| Which country is your headquarters located in: |
China |
Which countries do you do operate in:
(This includes countries you are conducting activities in) |
China
|
Contribution |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: |
New TB Drugs:
Rifampicin Type II, samller dosage less liver damage.
|
Declaration |
Declaration of interests:
No conflicts of interest were delacred.
|
| Application date: |
April 13, 2017 |
| Last updated: |
April 20, 2018 |
|
